professional documents
home
Upload
docsters
Upload
2 March 200 I FDA Office of Consumer PLffairs Advisory Committees Desk 5600 Fishers Lane, Room I6-85 Rockville, Maryland 20857 Dear Consumer Representative: My name is Michael Grosh and I am junior in college. I am writing you today to show my concern with the use of genetic engineering in food production. By now, millions of acres of geneticallyengineered crops have been planted, and nearly two-thirds of the products on our supermarket shelves contain genetically engineered ingredients. But GE foods remain poorly studied; scientists simply cannot say with any authority that they are absolutely safe for human consumption. Essentially, we have been subjected to a massive experiment on human health. This, along with other potential dangers, is why the Food and Drug Administration should ban the use of genetic engineering in the production of food. According to studies, genetic engineering is a young and in many ways poorly understood technology. Many scientists believe that genetically engineered foods have been rushed much too quickly to market -to boost multinationals’ profit margins - before adequate testing has been completed to ensure public health. The Washington Post states that the dearth of studies is the legacy of a U.S. poiicy that considers gene-altered plants and food to be fbndamentally the same as conventional ones, a policy some Americans are starting to question. It is also the legacy of broken promises by the Food and Drug Administration and the Environmental Protection Agency that is inciting these questions. The FDA has consistently maintained that GE foods are safe, even though many scientists disagree. In June 1999, the Alliance for Bio-Integrity - one of the parties in a lawsuit against the FDA to force the agency to label GE foods - received internal FDA documents that show that some of the FDA’s own scientists have doubts about the safety of genetically engineered foods. Gne potential danger genetic engineering is that it may trigger allergies in people. Genetic engineering may involve the transfer of new and unidentified proteins from one food to another, with the potential of causing allergic reactions. These allergies are not simpIe a matter of slight discomfort; they can potentially result in life-threatening anaphylactic shock. Without labeling, people with allergies will not know whether they are eating foods that contain genes from other foods to which they are allergic. This massive experiment on human health will continue unless the Food and Drug Administration takes the initiative to stop the use of genetic engineering in the production of food. Even if you shop at the local health food store, you may be eating some genetically engineered foods. So as a consumer representative I trust you will consider my points to be valid and initiate a change not just for me, but for the entire American public. Michael Grosh 1080 14* street Boulder, Colorado 80,192 t & , ,, .ll . . ) .“( I; . . j ,’
flag this doc
16
0
not rated
0
5/5/2008
English
Preview

FDA A fillable

GovernmentDocs 5/4/2008 | 404 | 4 | 0 | legal
Preview

FDA Regulatory Pathway Annual FDA and the Changing

GovernmentDocs 5/4/2008 | 168 | 2 | 0 | legal
Preview

Irradiation of Food An FDA Perspective

GovernmentDocs 5/4/2008 | 136 | 2 | 0 | legal
Preview

Irradiation of Food An FDA Perspective Packaging

FDADocs 5/8/2008 | 120 | 1 | 0 | legal
Preview

FDA Field Inspections

FDADocs 5/5/2008 | 112 | 0 | 0 | legal
Preview

FDA Organizational Chart

FDADocs 5/8/2008 | 314 | 3 | 0 | legal
Preview

FDA Assistance to Industry

FDADocs 5/9/2008 | 140 | 1 | 0 | legal
Preview

FDA in the International Community

FDADocs 5/9/2008 | 112 | 0 | 0 | legal
Preview

FDA s Accomplishments in 2005

FDADocs 5/9/2008 | 93 | 0 | 0 | legal
Preview

FDA Receipt for Samples

FDADocs 5/9/2008 | 142 | 1 | 0 | legal
Preview

AFFIDAVIT IN TRANSIT FDA

FDADocs 5/9/2008 | 78 | 0 | 0 | legal
Preview

NOTICE OF FDA ACTION

FDADocs 5/9/2008 | 134 | 0 | 0 | legal
Preview

FDA Information Page

FDADocs 5/9/2008 | 104 | 0 | 0 | legal
Preview

Vaccine Safety An FDA Perspective

FDADocs 5/5/2008 | 108 | 3 | 0 | legal
Preview

FDA Forum handheld Doppler safety

FDADocs 5/9/2008 | 61 | 0 | 0 | legal
Preview

Pfizer DTC Hearing Abstract

FDADocs 5/12/2008 | 142 | 1 | 0 | legal
Preview

ROTARIX Rotavirus Vaccine Live Oral

FDADocs 5/12/2008 | 279 | 1 | 0 | legal
Preview

Section Pharmacological Research of VasoCleaner on Hyperlipidemia and Atherosclerosis

FDADocs 5/12/2008 | 157 | 1 | 0 | legal
Preview

Section Documents regarding a Chinese Patent of the herbal formuIation

FDADocs 5/12/2008 | 159 | 1 | 0 | legal
Preview

Section Toxicological tests of VasoCleaner in Mice and Rats

FDADocs 5/12/2008 | 109 | 2 | 0 | legal
Preview

June Pre Market Notification Letter

FDADocs 5/12/2008 | 122 | 0 | 0 | legal
Preview

Report on toxicity test of Xiwang capsule

FDADocs 5/12/2008 | 228 | 0 | 0 | legal
Preview

August letter to Christopher Weisberg P A

FDADocs 5/12/2008 | 181 | 0 | 0 | legal
Preview

Laboratoires Laphal DRD B P Allauch CEDEX France

FDADocs 5/12/2008 | 265 | 0 | 0 | legal
Preview

Transmittal Letter and July letter to Christopher Weisberg P A

FDADocs 5/12/2008 | 113 | 0 | 0 | legal
 
review this doc